96 weeks results from two African studies confirm dolutegravir non-inferiority but highlight continued weight gain
Islatravir plus doravirine maintains viral suppression for a year
Rapid weight gain after switching to TAF, regardless of other HIV drugs taken
Starting infant treatment within days of birth does not improve viral suppression
Amsterdam's strategy to detect and treat acute HIV dramatically reduces time to viral suppression
The human stories behind the treat-all policy in eSwatini
Weight gain after starting HIV treatment may have genetic influences
Community-based HIV treatment superior to clinic-based care for men in South Africa
Weight gain on HIV treatment: more common with newer drugs, low CD4 counts
